DK1558730T3 - Inhibitorresistent HCV-NS3-protease - Google Patents

Inhibitorresistent HCV-NS3-protease

Info

Publication number
DK1558730T3
DK1558730T3 DK03770808T DK03770808T DK1558730T3 DK 1558730 T3 DK1558730 T3 DK 1558730T3 DK 03770808 T DK03770808 T DK 03770808T DK 03770808 T DK03770808 T DK 03770808T DK 1558730 T3 DK1558730 T3 DK 1558730T3
Authority
DK
Denmark
Prior art keywords
protease
inhibitor
resistant
hcv
resistant hcv
Prior art date
Application number
DK03770808T
Other languages
English (en)
Inventor
George Kukolj
Lisette Lagace
Martin Marquis
Daniel Lamarre
Arnim Pause
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1558730T3 publication Critical patent/DK1558730T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Photolithography (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • External Artificial Organs (AREA)
  • Enzymes And Modification Thereof (AREA)
DK03770808T 2002-10-29 2003-10-24 Inhibitorresistent HCV-NS3-protease DK1558730T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42194302P 2002-10-29 2002-10-29
PCT/CA2003/001636 WO2004039970A1 (en) 2002-10-29 2003-10-24 Inhibitor-resistant hcv ns3 protease

Publications (1)

Publication Number Publication Date
DK1558730T3 true DK1558730T3 (da) 2008-05-26

Family

ID=32230287

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03770808T DK1558730T3 (da) 2002-10-29 2003-10-24 Inhibitorresistent HCV-NS3-protease

Country Status (13)

Country Link
US (1) US7208309B2 (da)
EP (1) EP1558730B1 (da)
JP (1) JP4295222B2 (da)
AT (1) ATE385253T1 (da)
AU (1) AU2003280239B2 (da)
CA (1) CA2498653C (da)
DE (1) DE60318954T2 (da)
DK (1) DK1558730T3 (da)
ES (1) ES2298585T3 (da)
IL (1) IL168254A (da)
MX (1) MXPA05004276A (da)
NZ (1) NZ540292A (da)
WO (1) WO2004039970A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000308A2 (en) * 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
EP1678202B1 (en) * 2003-10-27 2012-06-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
EP1713822B1 (en) 2004-01-30 2010-03-17 Medivir AB Hcv ns-3 serine protease inhibitors
US20090081636A1 (en) * 2005-04-11 2009-03-26 Mingjun Huang Pharmaceutical compositions for and methods of inhibiting HCV replication
US7465537B2 (en) * 2005-05-01 2008-12-16 The Board Of Trustees Of The University Of Arkansas Compounds and methods for inhibiting hepatitis C virus replication
WO2007014174A2 (en) * 2005-07-25 2007-02-01 Gilead Sciences, Inc. Drug-resistant mutants of hepatitis c virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
KR20080072906A (ko) * 2005-11-11 2008-08-07 버텍스 파마슈티칼스 인코포레이티드 Ｃ형 간염 바이러스 변이체
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2121991A2 (en) 2006-10-20 2009-11-25 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
WO2008112108A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. In vivo hcv resistance to anti-viral inhibitors
US8298541B2 (en) 2007-03-29 2012-10-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae
EP2342336B1 (en) 2008-09-05 2016-12-14 President and Fellows of Harvard College Continuous directed evolution of proteins and nucleic acids
EP2655614B1 (en) 2010-12-22 2017-03-15 President and Fellows of Harvard College Continuous directed evolution
CA2840828A1 (en) * 2011-07-06 2013-01-10 Gilead Sciences, Inc. Hcv genotype 3 replicons
EP2729490A1 (en) 2011-07-06 2014-05-14 Gilead Sciences, Inc. Hcv genotype 4 replicons
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
WO2020205510A1 (en) 2019-03-29 2020-10-08 Trustees Of Boston University Chimeric antigen receptor (car) modulation
US11572565B2 (en) 2020-07-21 2023-02-07 Trustees Of Boston University Inducible control of gene expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6326137B1 (en) * 1999-06-25 2001-12-04 Schering Corporation Hepatitis C virus protease-dependent chimeric pestivirus
US20050074465A1 (en) * 1999-11-24 2005-04-07 Michael Houghton HCV fusion proteins with modified NS3 domains
US6986892B1 (en) * 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
AU2002218906B2 (en) * 2000-12-22 2006-08-03 Boehringer Ingelheim (Canada) Ltd. Self-replicating RNA molecule from hepatitis C virus
WO2002068933A2 (en) * 2001-02-28 2002-09-06 The Scripps Research Institute Small molecule design against drug resistant mutants using directed evolution
EP1678202B1 (en) 2003-10-27 2012-06-13 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants

Also Published As

Publication number Publication date
CA2498653A1 (en) 2004-05-13
EP1558730B1 (en) 2008-01-30
IL168254A (en) 2010-11-30
ES2298585T3 (es) 2008-05-16
US20050019753A1 (en) 2005-01-27
JP4295222B2 (ja) 2009-07-15
AU2003280239A1 (en) 2004-05-25
ATE385253T1 (de) 2008-02-15
DE60318954T2 (de) 2009-01-22
MXPA05004276A (es) 2005-08-03
CA2498653C (en) 2010-12-14
JP2006503584A (ja) 2006-02-02
NZ540292A (en) 2006-09-29
US7208309B2 (en) 2007-04-24
EP1558730A1 (en) 2005-08-03
AU2003280239B2 (en) 2009-03-12
DE60318954D1 (de) 2008-03-20
WO2004039970A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
IL168254A (en) Inhibitor-resistant hcv ns3 protease
WO2004101602A3 (en) Hepatitis c inhibitor peptide analogs
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
HK1081196A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
SI1481000T1 (sl) Novi peptidi kot inhibitorji NS serin proteaze virusa hepatitisa C
IL152022A0 (en) Compounds useful as protease inhibitors and pharmaceutical compositions containing the same
DE602005015834D1 (de) 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
RS67004A (en) Macrocyclic peptides active against the hepatitis c virus
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
HK1090644A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
HK1098164A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
EA200400986A1 (ru) Гетероциклические трипептиды в качестве ингибиторов вируса гепатита c
HK1095594A1 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2002048116A3 (en) Inhibitors of hepatitis c virus ns3 protease
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
WO2004014852A3 (en) Iminothiazolidinones as inhibitors of hcv replication
AU2003259155A1 (en) Pharmaceutical compositions comprising hepatitis c viral protease inhibitors
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
Bennett et al. The identification of α-ketoamides as potent inhibitors of hepatitis c virus nS3-4a proteinase
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
WO2003095475A8 (en) Peptide compounds and their use as protease substrates